0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Mirum Pharmaceuticals Inc

Healthcare US MIRM

24.49USD
0.47(1.96%)

Last update at 2024-04-25T20:04:00Z

Day Range

23.1424.62
LowHigh

52 Week Range

17.5435.56
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -142.07100M -83.95100M -103.26400M -52.53200M -17.34800M
Minority interest - - - - 0.00000M
Net income -135.66500M -83.98800M -103.27000M -52.55300M -17.34800M
Selling general administrative 89.07M 59.22M 22.69M 11.75M 0.58M
Selling and marketing expenses - - - - -
Gross profit 64.69M 17.23M - - 0.00000M
Reconciled depreciation 3.68M 0.97M 0.62M 0.32M -
Ebit -131.22000M -173.41300M -104.29600M -55.06700M -4.37400M
Ebitda -126.99800M -64.65400M -102.92900M -54.74300M -
Depreciation and amortization 4.22M 108.76M 1.37M 0.32M -
Non operating income net other 4.22M -0.21600M 1.37M - 0.00000M
Operating income -131.22000M -173.41300M -104.29600M -54.74300M -17.40600M
Other operating expenses 208.28M 192.55M 104.30M 54.74M 0.00000M
Interest expense 15.98M 17.59M 0.34M 2.54M 0.00000M
Tax provision -6.40600M 0.04M 0.00600M 0.02M -
Interest income 3.86M 0.37M 1.56M 2.23M 0.06M
Net interest income -12.12200M -17.22400M 1.22M 2.23M -
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -6.40600M 0.04M 0.00600M 0.02M 0.00000M
Total revenue 77.06M 19.14M 0.00000M 0.00000M 0.00000M
Total operating expenses 195.91M 190.65M 104.30M 54.74M 4.37M
Cost of revenue 12.37M 1.90M - - 0.00000M
Total other income expense net -10.85100M 89.46M 1.03M 2.21M -21.64800M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -135.66500M -83.98800M -103.27000M -52.55300M -26.02200M
Net income applicable to common shares -135.66500M -83.98800M -103.27000M -52.55300M -26.02200M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 352.91M 294.65M 240.86M 146.71M 51.98M
Intangible assets 58.95M 18.74M - - 0.00000M
Earning assets - - - - -
Other current assets 8.95M 5.27M 4.53M 2.70M 0.01M
Total liab 210.87M 174.44M 68.77M 16.36M 62.30M
Total stockholder equity -392.82400M 120.21M -173.17100M -69.90100M -10.32300M
Deferred long term liab - 0.20M - - 0.00000M
Other current liab 55.11M 2.00M 1.26M 9.33M 2.18M
Common stock 0.00400M 0.00300M 0.00300M 0.00200M 6.99M
Capital stock 0.00400M 0.00300M 0.00300M 0.00200M 6.99M
Retained earnings -392.82400M -257.15900M -173.17100M -69.90100M -17.34800M
Other liab 144.88M 129.94M 47.68M 0.04M 6.99M
Good will - - - - 0.00000M
Other assets 101.38M 101.79M 3.22M 0.32M 0.00000M
Cash 28.00M 31.34M 142.09M 139.95M 51.96M
Cash and equivalents - - - - -
Total current liabilities 64.73M 42.60M 18.46M 13.08M 2.45M
Current deferred revenue - 30.72M 13.41M - -
Net debt -25.81500M -28.72600M -138.82300M -136.30400M -51.96300M
Short term debt 0.93M 0.71M 0.64M 0.40M 0.00000M
Short long term debt - - - - 0.00000M
Short long term debt total 2.19M 2.61M 3.26M 3.65M -
Other stockholder equity 0.21M 377.40M -0.08600M -146.84300M 0.03M
Property plant equipment 0.91M 0.98M 1.29M 3.73M 0.00000M
Total current assets 190.22M 166.59M 236.35M 119.36M 51.98M
Long term investments 0.00000M 4.98M 0.00000M 23.29M 0.00000M
Net tangible assets 83.08M 101.47M 172.09M 130.35M -17.31300M
Short term investments 123.72M 125.20M 89.73M 104.69M 0.00000M
Net receivables 23.99M 3.27M - - -
Long term debt - - - - 0.00000M
Inventory 5.57M 1.51M - - 0.00000M
Accounts payable 8.69M 9.17M 3.15M 3.35M 0.27M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -0.21700M -0.03500M 0.08M 0.13M 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity 0.00400M 0.00300M 0.00300M 0.00200M 6.99M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity -392.82400M -257.15900M -173.17100M - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 101.38M 101.79M 1.27M 0.32M 0.00000M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 162.68M 128.06M 4.51M 27.35M 0.00000M
Capital lease obligations 2.19M 2.61M 3.26M 3.65M 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 7.98M -42.42900M 11.34M -127.78100M -127.50000M
Change to liabilities 7.64M 22.66M 3.68M 10.06M 3.67M
Total cashflows from investing activities 7.70M 48.55M 37.87M -127.78100M -11.25000M
Net borrowings - - -0.15800M - 0.07M
Total cash from financing activities 109.09M 73.47M 181.29M 127.18M 89.75M
Change to operating activities -4.51400M -5.17700M -3.07200M -2.93500M -0.01800M
Net income -135.66500M -83.98800M -103.27000M -52.55300M -26.02200M
Change in cash -3.33700M -10.74600M 130.12M -39.99300M 77.94M
Begin period cash flow 131.34M 142.09M 11.97M 51.96M -
End period cash flow 128.00M 131.34M 142.09M 11.97M 51.96M
Total cash from operating activities -120.13600M -132.75800M -89.07500M -39.36200M -0.55950M
Issuance of capital stock 107.37M 9.01M 131.87M 127.18M -
Depreciation 3.68M 0.97M 0.62M 0.32M 0.32M
Other cashflows from investing activities - 91.00M 26.76M -127.50000M 108.00M
Dividends paid - 0.00000M - - 0.00000M
Change to inventory -3.44800M -0.49500M -0.49500M -0.49500M -0.49500M
Change to account receivables -20.72700M -20.72700M -20.72700M -20.72700M 0.00000M
Sale purchase of stock 15.59M 9.01M 131.87M 127.18M 59.79M
Other cashflows from financing activities -13.86500M 64.45M 49.42M 59.98M 49.42M
Change to netincome 27.01M 23.09M 12.55M 5.74M 21.81M
Capital expenditures 0.28M 19.02M 0.23M 0.28M 0.28M
Change receivables -20.72700M - - - 0.00000M
Cash flows other operating 3.52M 121.53M -2.41900M - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes -3.34900M -10.74500M 130.09M - 0.00000M
Change in working capital -21.05000M 16.98M 0.61M 7.12M -
Stock based compensation 27.01M 23.09M 12.55M 6.07M -
Other non cash items 12.47M -90.41000M 0.34M -0.32600M -
Free cash flow -120.41400M -151.78200M -89.30000M -39.64300M -

Fundamentals

  • Previous Close 24.02
  • Market Cap1449.24M
  • Volume816010
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-104.19400M
  • Revenue TTM144.73M
  • Revenue Per Share TTM3.76
  • Gross Profit TTM 64.69M
  • Diluted EPS TTM-4.27

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MIRM
Mirum Pharmaceuticals Inc		 0.47 1.96% 24.49 - 109.89 9.92 5.33 9.93 -10.2364
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals Inc

950 Tower Lane, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Mr. Christopher Peetz Pres, CEO & Director 1979
Dr. Ian Clements Chief Financial Officer 1969
Mr. Peter Radovich M.B.A., Ph.D. Chief Operating Officer 1978
Mr. Paul K. Ross Chief Compliance Officer NA
Ms. Erin Campany Sr. VP of HR 1968
Dr. Pamela Vig Ph.D. Head of R&D 1971
Ms. Lara Longpre MBA, MSC Chief Devel. Officer 1970
Ms. Vinita P. Kumar Sr. vice Pres of Quality NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).